Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis has introduced Bicalutamide tablets in the UK, Germany and France. Bicalutamide Actavis is said to be the first generic version of the oncology drug to be made available in the three markets.
Subscribe to our email newsletter
Actavis’s Bicalutamide, the generic version of AstraZeneca’s Casodex, is used as a treatment for prostate cancer and will be available in tablet form in 50mg doses in all three markets, as well as in 150mg doses in the UK.
Svend Andersen, executive vice president of Western Europe sales at Actavis, said: “We are pleased to be the first generic pharmaceutical company to bring this product to the market – creating value for patients at a lower price. Bicalutamide is an important product in Actavis’s portfolio.”